In our clinical material, the BCT intervention was most frequently possible in patients with luminal A breast cancer (62.9% of analyzed cases), while BCT was the least frequently performed in patients diagnosed as HER2-positive (3.8% of women qualified for the study). The gene discussed is ERBB2; the disease is breast carcinoma.